Rongrong Zhou1,2, Cristina Llorente2, Jinling Cao2,3, Bei Gao2, Yi Duan2, Lu Jiang2, Yanhan Wang2, Vipin Kumar2, Peter Stärkel4, Lars Bode5, Xuegong Fan1, Bernd Schnabl2,6. 1. From the Department of Infectious Diseases, Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha, China. 2. Department of Medicine, University of California San Diego, La Jolla, California, USA. 3. College of Food Science and Engineering, Shanxi Agricultural University, Taigu, China. 4. St Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. 5. Department of Pediatrics and Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence (MOMI CORE), University of California San Diego, La Jolla, California, USA. 6. Department of Medicine, VA San Diego Healthcare System, San Diego, California, USA.
Abstract
BACKGROUND: Fucosyltransferase 2 (Fut2)-mediated intestinal α1-2-fucosylation is important in maintaining a symbiotic host-microbiota relationship and can protect against several pathogens. Intestinal dysbiosis is an important factor for the progression of experimental ethanol (EtOH)-induced liver disease, but the role of Fut2 in modulating the intestinal glycocalyx during alcohol-associated liver disease is unknown. We investigated the role of Fut2-mediated intestinal α1-2-fucosylation for the development of alcohol-associated liver disease. METHODS: Immunohistochemistry staining was applied to evaluate α1-2-fucosylation in duodenal biopsies from patients with alcohol use disorder. Wild-type (WT) and Fut2-deficient littermate mice were subjected to Lieber-DeCarli models of chronic EtOH administration and the chronic-binge EtOH diet (NIAAA model). RESULTS: Intestinal α1-2-fucosylation was down-regulated in patients with alcohol use disorder. Lack of α1-2-fucosylation in Fut2-deficient mice exacerbates chronic EtOH-induced liver injury, steatosis, and inflammation without affecting EtOH metabolism. Dietary supplementation of the α1-2-fucosylated glycan 2'-fucosyllactose (2'-FL) ameliorates EtOH-induced liver disease in Fut2-deficient mice in the NIAAA model. Despite no direct effects on growth of Enterococcus faecalis in vitro, intestinal α1-2-fucosylation reduces colonization of cytolysin-positive E. faecalis in the intestine of EtOH-fed mice. CONCLUSIONS: Intestinal α1-2-fucosylation acts as a host-protective mechanism against EtOH-induced liver disease. 2'-FL is an oligosaccharide naturally present in human milk that could be considered as therapeutic agent for alcohol-associated liver disease.
BACKGROUND: Fucosyltransferase 2 (Fut2)-mediated intestinal α1-2-fucosylation is important in maintaining a symbiotic host-microbiota relationship and can protect against several pathogens. Intestinal dysbiosis is an important factor for the progression of experimental ethanol (EtOH)-induced liver disease, but the role of Fut2 in modulating the intestinal glycocalyx during alcohol-associated liver disease is unknown. We investigated the role of Fut2-mediated intestinal α1-2-fucosylation for the development of alcohol-associated liver disease. METHODS: Immunohistochemistry staining was applied to evaluate α1-2-fucosylation in duodenal biopsies from patients with alcohol use disorder. Wild-type (WT) and Fut2-deficient littermate mice were subjected to Lieber-DeCarli models of chronic EtOH administration and the chronic-binge EtOH diet (NIAAA model). RESULTS: Intestinal α1-2-fucosylation was down-regulated in patients with alcohol use disorder. Lack of α1-2-fucosylation in Fut2-deficient mice exacerbates chronic EtOH-induced liver injury, steatosis, and inflammation without affecting EtOH metabolism. Dietary supplementation of the α1-2-fucosylated glycan 2'-fucosyllactose (2'-FL) ameliorates EtOH-induced liver disease in Fut2-deficient mice in the NIAAA model. Despite no direct effects on growth of Enterococcus faecalis in vitro, intestinal α1-2-fucosylation reduces colonization of cytolysin-positive E. faecalis in the intestine of EtOH-fed mice. CONCLUSIONS: Intestinal α1-2-fucosylation acts as a host-protective mechanism against EtOH-induced liver disease. 2'-FL is an oligosaccharide naturally present in human milk that could be considered as therapeutic agent for alcohol-associated liver disease.
Authors: Arthur W Yan; Derrick E Fouts; Johannes Brandl; Peter Stärkel; Manolito Torralba; Eckart Schott; Hide Tsukamoto; Karen E Nelson; David A Brenner; Bernd Schnabl Journal: Hepatology Date: 2010-12-10 Impact factor: 17.425
Authors: Pirjo Wacklin; Harri Mäkivuokko; Noora Alakulppi; Janne Nikkilä; Heli Tenkanen; Jarkko Räbinä; Jukka Partanen; Kari Aranko; Jaana Mättö Journal: PLoS One Date: 2011-05-19 Impact factor: 3.240
Authors: Purna C Kashyap; Angela Marcobal; Luke K Ursell; Samuel A Smits; Erica D Sonnenburg; Elizabeth K Costello; Steven K Higginbottom; Steven E Domino; Susan P Holmes; David A Relman; Rob Knight; Jeffrey I Gordon; Justin L Sonnenburg Journal: Proc Natl Acad Sci U S A Date: 2013-09-23 Impact factor: 11.205
Authors: Eveline Gart; Kanita Salic; Martine C Morrison; Martin Giera; Joline Attema; Christa de Ruiter; Martien Caspers; Frank Schuren; Ivana Bobeldijk-Pastorova; Marianne Heer; Yan Qin; Robert Kleemann Journal: Front Nutr Date: 2022-06-17
Authors: Benjamin P Kellman; Anne Richelle; Jeong-Yeh Yang; Digantkumar Chapla; Austin W T Chiang; Julia A Najera; Chenguang Liang; Annalee Fürst; Bokan Bao; Natalia Koga; Mahmoud A Mohammad; Anders Bech Bruntse; Morey W Haymond; Kelley W Moremen; Lars Bode; Nathan E Lewis Journal: Nat Commun Date: 2022-05-04 Impact factor: 17.694